3 years perfecting a new class of drug and treatment to perfect its its efficacy, safety and test its shelf life chemical stability is nothing, especially when one is operating at the very bleeding edge of human knowledge as is the case regarding MPL's effect on the mTOR system (let alone eyerything else in the body of the patient)..
The average length of time to develop a new drug is 11 years. They're 7 years into it, and that includes a setback of 3 years due to the capsules back in 2016/17 and they're in phase IIb dog trials and ready to go this year with the first phase II human trials (MND0 And note, phase II must be done with the drug that they intend to commercialise..
Either you're an ignoramous concerning biotech R&D matters or you're a fake with your "concerns". Please choose.
3 years perfecting a new class of drug and treatment to perfect...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |